Welcome to our dedicated page for Dianthus Therapeutics news (Ticker: DNTH), a resource for investors and traders seeking the latest updates and insights on Dianthus Therapeutics stock.
Dianthus Therapeutics develops next-generation therapies for severe autoimmune and inflammatory diseases as a clinical-stage biotechnology company. Its updates center on claseprubart, an investigational monoclonal antibody engineered to selectively inhibit the active form of C1s in the classical complement pathway, with programs in chronic inflammatory demyelinating polyneuropathy, generalized myasthenia gravis and multifocal motor neuropathy.
Recurring company news also covers FDA interactions and designations, clinical and preclinical program updates, financial results, public equity offerings, pre-funded warrants, and inducement equity grants under Nasdaq rules. Additional disclosures address DNTH212 and the company’s stated focus on rheumatology indications such as Sjögren’s disease, systemic lupus erythematosus and dermatomyositis.
Dianthus Therapeutics (Nasdaq: DNTH) announced two poster presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting in Savannah, Georgia. DNTH103 is an investigational classical pathway inhibitor specific to the active form of C1s, being evaluated for generalized Myasthenia Gravis, Multifocal Motor Neuropathy, and Chronic Inflammatory Demyelinating Polyneuropathy.
The presentations will showcase:
- Preclinical and in vitro data on DNTH103's potentially differentiated profile in disease models of gMG and CIDP
- Head-to-head affinity and pharmacodynamic potency data comparing DNTH103 to riliprubart
- DNTH103's sustainable inhibition of complement and prevention of nerve conduction velocity impairment in a CIDP preclinical model
- DNTH103 as a potentially safer and more convenient novel therapy for generalized Myasthenia Gravis
The posters will be available on the Dianthus website after presentation.
Dianthus Therapeutics (Nasdaq: DNTH), a clinical-stage biotech company focused on developing advanced antibody complement therapeutics for severe autoimmune diseases, has announced its participation in three major healthcare investor conferences in September 2024. CEO Marino Garcia will present corporate overviews at:
1. Baird 2024 Global Healthcare Conference on September 11 at 2:00 p.m. ET in New York City
2. Cantor 2024 Global Healthcare Conference on September 17 at 10:55 a.m. ET in New York City
3. Stifel 2024 Virtual Immunology and Inflammation Summit on September 18 at 10:30 a.m. ET via Zoom
Live webcasts of the Cantor and Stifel conference presentations will be available on the company's website under the Investors section.
Dianthus Therapeutics (Nasdaq: DNTH) reported Q2 2024 financial results and business updates. Key highlights include:
- Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing; top-line results expected in 2H'25
- IND cleared for Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy (MMN); top-line results anticipated in 2H'26
- Phase 2 trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to start 2H'24
- $360.7 million cash position, providing runway into 2H'27
- Q2 2024 net loss of $17.6 million or $0.51 per share
- R&D expenses increased to $18.1 million, G&A expenses rose to $6.0 million
DNTH103, the company's lead candidate, is advancing in multiple autoimmune indications with potential for best-in-class profile.
Dianthus Therapeutics announced two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology, held in Helsinki from June 29 to July 2, 2024. DNTH103 is an investigational inhibitor targeting the active form of C1s, being evaluated for the treatment of severe neuromuscular conditions like generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy. The presentations will showcase preclinical and in vitro data, highlighting DNTH103's potential advantages over existing treatments. The CEO emphasized DNTH103's potential for safer, more convenient administration with consistent symptom control and fewer risks compared to current therapies.
Dianthus Therapeutics has received FDA clearance to start a Phase 2 trial for DNTH103 in treating Multifocal Motor Neuropathy (MMN). This trial, named the MoMeNtum study, will assess the safety, tolerability, and efficacy of DNTH103 in 36 patients globally. The trial will follow a randomized, double-blind, placebo-controlled design, with patients receiving subcutaneous injections every two weeks for 17 weeks, followed by a 52-week open-label extension. Top-line results are expected in the second half of 2026. DNTH103, a potent C1s inhibitor, aims to offer a more convenient treatment option than current therapies. Dianthus is also building a neuromuscular franchise with planned trials in generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy in 2024.
Dianthus Therapeutics, a biotechnology company focused on antibody complement therapeutics for autoimmune diseases, will participate in the Jefferies Global Healthcare Conference.
The company’s CEO, Marino Garcia, will present a corporate overview on June 6, 2024, at 1:30 p.m. ET in New York.
A live webcast of the presentation will be accessible via the Investors section of Dianthus Therapeutics' website.
Dianthus Therapeutics, a clinical-stage biotech company, reported financial results for Q1 2024, highlighting the initiation of Phase 2 MaGic trial for gMG using DNTH103, with ongoing trials in MMN and CIDP. The company raised $377 million in cash through successful financing, projecting runway till 2027.
Dianthus Therapeutics, a clinical-stage biotechnology company, will participate in the Bank of America Securities 2024 Health Care Conference. The CEO will present a corporate overview, focusing on antibody complement therapeutics for severe autoimmune diseases.
Dianthus Therapeutics, Inc. announced the granting of equity awards to two new non-executive employees as inducements for their employment. The awards comprised non-qualified stock options for a total of 52,000 shares, with a 10-year term and an exercise price of $22.53 per share. The options vest gradually over a 3-year period, subject to specific conditions.
Summary not available.